Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visepegenatide in Chinese Obese Subjects
NCT06350812Phase 2Completed
- Sponsor
- PegBio
- Start
- May 2024
- Primary completion
- Nov 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity comparing PB-119 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 24 weeks. Started May 2024; status: completed.
02
Drugs
visepegenatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06350812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06350812.